THEORETICAL CHANGES IN NEONATAL HOSPITALIZATION COSTS AFTER THE INTRODUCTION OF PORCINE-DERIVED LUNG SURFACTANT (CUROSURF)

被引：12

作者：

EGBERTS, J

机构：

[1] Department of Obstetrics and Gynecology, University of Leiden

[2] Department of Obstetrics and Gynecology, Leiden University Hospital, Leiden, 2300 RC, Building 1, P3-P

来源：

PHARMACOECONOMICS | 1995年 / 8卷 / 04期

关键词：

D O I：

10.2165/00019053-199508040-00007

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

The aims of this study were to determine the effects of porcine-derived lung surfactant (PLS; 'Curosurf') therapy on mortality, periods of care and hospitalisation costs in a model cohort of 1000 premature neonates. In this cohort, 55% of the neonates would develop respiratory distress syndrome (RDS) and this would result in a mortality rate of 35%. The mortality rate among infants without RDS is 19%. Five modes of surfactant therapy were studied: (i) late rescue; (ii) early treatment; (iii) prophylaxis; (iv) multiple-dose treatment; and (v) high multiple-dose treatment. At a 55% incidence of RDS, we found that late rescue and single-dose treatment of severely ill neonates resulted in between 4 and 51 extra survivors, and that multiple-dose treatments increased the number of extra survivors by between 17 and 101. Early treatment and prophylaxis were found to be the most effective strategies, resulting in between 38 and 111 extra survivors. These 2 modes of surfactant therapy were also more effective than the other types of intervention at other incidences of RDS. The introduction of PLS therapy increased the total hospitalisation costs of the cohort of 1000 neonates [71 million Netherlands guilders (NLG) if no patients received surfactant] by 0.8 to 16.0% because of increased survival. Improved survival increased the mean period of intensive care by 0.5 to 12.6% and of nonintensive care by 0.6 to 16.0%, thereby increasing the need for more beds. Costs for PLS ranged from 0.3 to 1.2% of the total hospital costs. The additional costs of PLS therapy per additional survivor, compared with the 'do nothing' option, ranged from NLG68 034 to NLG136 233, and were lowest with prophylaxis and highest with high multiple-dose treatment. Savings in costs per survivor (0.2 to 4.1%) and nonsurvivor (5.1 to 23.1%) were highest with prophylaxis and early treatment, which were found to be the most cost effective of the strategies studied.

引用

页码：324 / 342

页数：19

共 36 条

[1]

Soli F.R., McQueen M.C., Respiratory distress syndrome, Effective care of the newborn infant, (1992)

[2]

Hoekstra R.E., Jackson J.C., Myers T.F., Et al., Improved neonatal survival following multiple doses of bovine surfactant in very premature neonates at risk for respiratory distress syndrome, Pediatrics, 88, (1991)

[3]

Kendig J.W., Notter R.H., Cox C., Et al., A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns less than 30 weeks’ gestation, N Engl J Med, 324, (1991)

[4]

Konishi M., Fujiwara T., Chida S., Et al., A prospective, randomized trial of early versus late administration of a single dose of surfactant-TA, Early Hum Dev, 29, (1992)

[5]

Early versus delayed neonatal administration of a synthetic surfactant: the judgment of OSIRIS, Lancet, 340, (1992)

[6]

Speer C.P., Robertson B., Curstedt T., Et al., Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single versus multiple doses of Curosurf, Pediatrics, 89, pp. 13-20, (1992)

[7]

Bevilacqua G., Halliday H., Parmigiani S., Et al., Controlled multicentre trial of early treatment with porcine natural surfactant for neonatal respiratory distress syndrome, J Perinat Med, 21, (1993)

[8]

Egberts J., de Winter J.P., Sedin G., Et al., Comparison of prophylaxis and rescue treatment with Curosurf in babies less than 30 weeks gestation: a randomized trial, Pediatrics, 92, (1993)

[9]

Egberts J., Walti H., Bevilacqua G., Meta analysis of three ‘prophylaxis versus rescue’ trials with Curosurf, VIII International Workshop on Surfactant Replacement, (1993)

[10]

Halliday H.L., Tarnow-Mordi W.O., Corcoran J.D., Et al., A multicentre randomised trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome (the Curosurf 4 trial), Arch Dis Childhood, 69, (1993)

← 1 2 3 4 →